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Sir,
We read with great interest the study of Michie et al (2010)
evaluating capecitabine-induced hypertriglyceridaemia (CIHT).
The authors suggest that it should be classified as a common
adverse effect and we fully agree with their recommendation
for targeted screening in patients with diabetes or pre-existing
hyperlipidaemia. Here we report an additional case of severe CIHT
in a patient with pre-existing hyperlipidaemia to focus attention on
possible mechanisms.
A 50-year-old woman with a history of breast cancer, treated by
surgery and hyperlipidaemia stabilised with pravastatin, was
diagnosed in January 2009 with a progression of her breast cancer.
Before receiving carboplatin, TAXOL (Bristol Myers Squibb,
France) and bevacizumab, cholesterolaemia level was 6.68mmoll
 1
(2.59gl
 1) and triglyceridemia level was 2.51mmoll
 1 (2.20gl
 1)
(Figure 1). During the 6-month treatment, a transient increase in
triglycerides was observed and pravastatin was replaced by
rosuvastatin. In July 2009, bevacizumab alone was administered
once a week as maintenance treatment. In August 2009, because of
secondary gastric and ganglion infiltration, carboplatin and taxol
were stopped and the patient received a combination of
capecitabine and bevacizumab. Nine cycles of this treatment were
scheduled. After six cycles, in December 2009, highly raised
triglycerides (26.77mmoll
 1 (23.48gl
 1)) and slightly raised
cholesterol levels (8.75mmoll
 1 (3.39gl
 1)) were observed, with-
out any clinical sign of pancreatitis. At no time had the patient
reported alcohol consumption or dietary changes and no weight
gain was observed. The replacement of rosuvastatin by fenofibrate
was followed 1 week later by a significant decrease in her
triglyceride level to 6.26mmoll
 1 (5.49gl
 1). However, 1 month
later, the triglycerides level again increased to 11.33gl
 1
(9.94mmoll
 1). Owing to both side effects and progression of
her cancer, capecitabine and bevacizumab were stopped and
replaced by fulvestrant (FASLODEX; Astrazeneca, Cheshire, UK).
A return to baseline triglyceridaemia values (3.27mmoll
 1
(2.87gl
 1)) was observed within 2 months.
Our case fulfils the criteria for a probable case of CIHT.
Concomitant bevacizumab was not suspected because the increase
in triglycerides during first-line chemotherapy resolved sponta-
neously, whereas treatment with rosuvastatin was unchanged.
We would like to propose two ways to improve our under-
standing of CIHT:
(i) A defect of lipoprotein lipase (LPL) is linked with an
accumulation of chylomicrons and/or of very low-density
lipoprotein (VLDL). Kurt et al (2006) suggest that CIHT may
appear more readily in individuals with hereditary LPL
deficiency. It is worth noting that LPL defect also occurs in
the case of an increase in its inhibitor (apolipoprotein CIII)
and/or a decrease in its activator (apolipoprotein CII). As far
as we know, the link between capecitabine and apolipoprotein
CII/CIII levels has never been explored. We suggest that
laboratory test of patient should include measure of LPL
activity as well as of apolipoprotein CII/CIII levels.
(ii) As a triple prodrug, capecitabine is designed to be sequentially
activated to 5-FU: capecitabine is hydrolysed in the liver
to 50-deoxy-5-fluorocytidine, which is then converted into
50-deoxy-5-fluorouridine (50-dFUR) and subsequently into
5-FU by thymidine phosphorylase. Many cases of severe
hypertriglyceridaemia were described with capecitabine, but
to the best of our knowledge only one study has dealt with the
influence of 5-FU on serum and it did not report any changes
in triglyceride level in human (Stathopoulos et al, 1995).
Recently, a case of recurrent grade-4 hypertriglyceridaemia in
a patient treated with capecitabine and tegafur/uracil was
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Figure 1 Clinical course of triglyceride (’) and cholesterol (m) levels in
patients, expressed in mmoll
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www.bjcancer.comreported (Yildiz et al, 2010). This observation of hypertrigly-
ceridaemia with another prodrug of 5-FU suggest that
capecitabine and tegafur might share a mechanism respon-
sible for hypertriglyceridaemia. Tegafur is bioactivated in
5-FU by thymidine phosphorylase in a single step. Considering
that this enzyme is also responsible for the phosphorylation of
50-DFUR in 5-FU, we suggest that thymidine phosphorylase
could have a role in the generation of hypertriglyceridaemia.
Thymidine kinase and thymidine phosphorylase compete
for thymidine, and catalyse opposing synthetic and cata-
bolic reactions implicated in proliferation and angiogenesis,
respectively (Brockenbrough et al, 2009). As a modification of
the expression and activity of thymidine kinase as well as a
strong increase in the secretory phospholipase-A2 was observed
in resistant colon cancer cells (Temmink et al, 2010), a link
between thymidine metabolic pathways and phospholipids
metabolism that may at least partially explain CIHT.
A lipid survey should be mandatory before initiation of
capecitabine or other 5-FU prodrugs. Patients with dyslipidaemia
should be closely monitored and further studied.
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